Who is sponsoring NCT04535739?

NCT04535739 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT04535739?

Interventions in NCT04535739: prophylactic cranial irradiation.

What condition does NCT04535739 study?

NCT04535739 studies Small-cell Lung Cancer.

Is NCT04535739 still recruiting?

NCT04535739 is currently status unknown. Last updated 2 September 2020.

Last reviewed 2020-09-02 · How we verify

NCT04535739

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study

Status unknown Phase 3 Last updated 2 September 2020

What this trial tests

Phase 3 trial testing prophylactic cranial irradiation in Small-cell Lung Cancer in 414 participants. Status unknown.

Timeline

1 July 2019

Primary endpoint
30 January 2022

30 June 2022

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	414
Start date	1 July 2019
Primary completion	30 January 2022
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

prophylactic cranial irradiation

Conditions studied

Small-cell Lung Cancer — all drugs for Small-cell Lung Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 65, any sex, with Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

prophylactic cranial irradiation （PCI）was verified to decrease the brain metastases rates and improve the overall survival（OS）for patients with limited stage small cell lung cancer.We hypothesis that patients with extensive-stage small cell lung cancer after chemotherapy and thoracic radiation can also benefit from PCI.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Prophylactic cranial irradiation in small cell lung cancer: an update.
Chu X, Zhu Z. · · 2023 · cited 6× · PMID 36421007 · DOI 10.1097/cco.0000000000000910
Current dilemma and future directions over prophylactic cranial irradiation in SCLC: a systematic review in MRI and immunotherapy era.
Tang L, Tian G, Li N. · · 2024 · cited 4× · PMID 39139283 · DOI 10.3389/fonc.2024.1382220
Prophylactic cranial irradiation for small cell lung cancer in the era of immunotherapy and molecular subtypes.
Pozonec V, Pozonec MD, Aigner C, Widder J, et al · · 2025 · cited 3× · PMID 39625049 · DOI 10.1097/cco.0000000000001111
Prophylactic cranial irradiation in ES-SCLC: The ongoing debate from the past to the immunotherapy Era".
Najdi T, Richa A, Chamieh M, Zeidan T, et al · · 2026 · PMID 41938987 · DOI 10.1016/j.ctro.2026.101153

Verify or expand the search:

Other recruiting trials for Small-cell Lung Cancer

Currently open trials in the same condition.

NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT07218146 — A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVAT · Phase 3 · recruiting
NCT07005128 — A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi · Phase 3 · recruiting
NCT06424067 — Phase 2 Study of Fingolimod in Lung Cancers · Phase 2 · recruiting
NCT06957314 — A Study of Hospital-at-Home for People Receiving Tarlatamab · NA · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04535739 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 2 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04535739.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing